Sales of some Eli Lilly drugs — including its best-selling product last year — appear to be softening, according to Wall Street analysts.
JPMorgan flagged similar trends for Trulicity, which led all Lilly drugs with $7.13 billion in sales for all of 2023.
The thesis is predicated on Eli Lilly growing faster than the broader pharmaceutical industry for years to come.
Over the past three years, shares of Eli Lilly have soared nearly 300%, compared with a 24% gain for the S & P 500 .
A box of the drug trulicity, made by Eli Lilly Pharmaceutical, sits on a counter at a pharmacy in Provo, Utah, January 9, 2020.
Persons:
Eli Lilly, Wells, Lilly, Mounjaro, Jim Cramer, tirzepatide, Zepbound, Eli Lilly's, Novo, Wegovy, drugmaker, Jim Cramer's, Jim, Eli Lilly Pharmaceutical, George Frey
Organizations:
Wall Street, JPMorgan, Club, Novo Nordisk, Novo, BMO Capital Markets, Drug Administration, FDA, The Club, CNBC
Locations:
Wells Fargo, Trulicity, Tirzepatide, Danish, Lilly, Provo , Utah